Stock Performance Review on Exact Sciences and Three Other Medical Research Stocks

Stock Research Monitor: DXCM, KANG, and NVTA

LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on EXAS sign up now at www.wallstequities.com/registration. On Friday, the NASDAQ Composite ended the day at 7,554.33, up 1.51%; the Dow Jones Industrial Average edged 0.90% higher, to finish at 24,635.21; and the S&P 500 closed at 2,734.62, gaining 1.08%. Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

DexCom

San Diego, California headquartered DexCom Inc.'s stock finished Friday's session 4.78% higher at $92.20 with a total trading volume of 1.44 million shares, which was higher than their three months average volume of 1.16 million shares. The stock has gained 24.07% in the past month, 67.97% over the past three months, and 37.92% in the previous twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 18.31% and 45.96%, respectively. Moreover, shares of DexCom, which focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have a Relative Strength Index (RSI) of 79.27.

On May 11^th, 2018, research firm Bank of America/ Merrill initiated a 'Buy' rating on the Company's stock, with a target price of $100 per share. Get the full research report on DXCM for free by clicking below at:

www.wallstequities.com/registration/?symbol=DXCM

Exact Sciences

Shares in Madison, Wisconsin headquartered Exact Sciences Corp. ended last Friday's session flat at $59.54 with a total trading volume of 2.05 million shares. The stock has gained 19.41% in the past month, 31.09% in the previous three months, and 55.70% over the past twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 24.66% and 21.34%, respectively. Moreover, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, have an RSI of 75.22. Gain free access to the research report on EXAS at:

www.wallstequities.com/registration/?symbol=EXAS

iKang Healthcare Group

On Friday, Beijing, China headquartered iKang Healthcare Group Inc.'s stock closed the day flat at $20.38. A total volume of 258,146 shares was traded. The Company's shares have advanced 21.82% in the previous three months and 33.29% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.33% and 25.05%, respectively. Additionally, shares of iKang Healthcare, which together with its subsidiaries, provides preventive healthcare solutions in China, have an RSI of 66.94. Register for your free report coverage on KANG at:

www.wallstequities.com/registration/?symbol=KANG

Invitae

Shares in San Francisco, California headquartered Invitae Corp. ended the day 1.35% higher at $7.50. A total volume of 393,814 shares was traded. The stock has gained 36.36% in the last month. The Company's shares are trading above their 50-day moving average by 23.20%. Furthermore, shares of Invitae, which processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the US, Canada, and internationally, have an RSI of 66.26. Get the free research report on NVTA at:

www.wallstequities.com/registration/?symbol=NVTA

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities